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Abstract
Background
The exclusion of other diseases that canmimic multiple sclerosis (MS) is the cornerstone of current
diagnostic criteria. However, data on the frequency of MS mimics in real life are incomplete.
Methods
A total of 695 patients presenting with symptoms suggestive of MS in any of the 22 RIREMS
centers underwent a detailed diagnostic workup, including a brain and spinal cord MRI scan,
CSF and blood examinations, and a 3-year clinical and radiologic follow-up.
Findings
A total of 667 patients completed the study. Alternative diagnoses were formulated in 163 (24.4%)
cases, the most frequent being nonspeciﬁc neurologic symptoms in association with atypical MRI
lesions of suspected vascular origin (40 patients), migraine with atypical lesions (24 patients), and
neuromyelitis optica (14 patients).MSwas diagnosed in 401 (60.1%) patients according to the 2017
diagnostic criteria. The multivariate analysis revealed that the absence of CSF oligoclonal immu-
noglobulin G bands (IgG-OB) (odds ratio [OR] 18.113), the presence of atypical MRI lesions (OR
10.977), the absence of dissemination in space (DIS) of the lesions (OR 5.164), and normal visual
evoked potentials (OR 3.550) were all independent predictors of an alternative diagnosis.
Interpretation
This observational, unsponsored, real-life study, based on clinical practice, showed that diseases
that mimicked MS were many, but more than 45% were represented by nonspeciﬁc neurologic
symptoms with atypical MRI lesions of suspected vascular origin, migraine, and neuromyelitis
optica. The absence of IgG-OB and DIS, the presence of atypical MRI lesions, and normal
visual evoked potentials should be considered suggestive of an alternative disease and red ﬂags
for the misdiagnosis of MS.
RELATED ARTICLE
Editorial
Diﬀerential diagnosis of
multiple sclerosis: The
better explanations in
clinical practice
Page 1037
MORE ONLINE
CME Course
NPub.org/cmelist
From the Departments of Neuroscience, Biomedicine and Movement (M.C., A. Gajofatto) and Neurological and Movement Sciences (G.S.), University of Verona; Department of
Neurosciences (C.G., C.T.), Azienda Ospedaliera San Camillo Forlanini, Roma; Department of Basic Medical Sciences, Neurosciences and Sense Organs (C.T., D.P.), University of Bari;
Policlinico Gemelli (G.F.), Rome; Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (BIONEC) (P.R.), Universita` di Palermo; Istituto Neurologico Mediterraneo (R.F.),
Pozzilli; Department of Neurology and Psychiatry (L.P.), Sapienza University of Rome; Multiple Sclerosis Center (P.A.), ASST Valle Olona, PO di Gallarate; Multiple Sclerosis Center (C.C.),
Ospedale di Montichiari, Spedali Civili di Brescia; Clinica Neurologica (M.D.), Dipartimento di Medicina, Universita` di Perugia; Department of Biomedical, Metabolic and Neurosciences
(D.F.), University of Modena and Reggio Emilia, Modena; Neurologia 2-CRESM (S.M.), AOU San Luigi Gonzaga, Orbassano; Multiple Sclerosis Centre (S.L.), A.O.U. Policlinico-Vittorio
Emanuele, Catania; Neurology Clinic (G.D.), Multiple Sclerosis Center, SS. Annunziata Hospital, Chieti; Department of Medicine, Surgery and Neuroscience (M.L.S.), University of Siena;
Department of Medical Science and Public Health (E.C.), University of Cagliari; Department of Medical, Surgical, Neurological, Metabolic and Aging Science (A. Gallo), University of
Campania; Department of Neuroscience, Reproductive Sciences (R.L.), University Federico II, Naples, Italy; Institute of Psychological Medicine and Clinical Neurosciences (V.T.), Cardiff
University School of Medicine, UK; Ospedale di Vaio (I.P.), Centro SM, Fidenza, Parma; Ospedale San Raffaele (M.E.R.), Milan; and Department of Rehabilitation (C.S.), Mons L Novarese
Hospital, Moncrivello, Italy.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was funded by the University of Verona.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. e2527
Multiple sclerosis (MS) diagnostic criteria have evolved over
time with an increasing use of paraclinical markers, especially
MRI,1–4 to enable a deﬁnite diagnosis earlier than clinical fea-
tures alone would allow.5,6 Despite technological advance-
ments, current diagnostic criteria still rely on key principles of
MS diagnosis articulated in the mid-20th century: demonstra-
tion of dissemination in space and in time of demyelinating
lesions and exclusion of alternative explanations.1–4,7
The 2010 and, more recently, the 2017 McDonald diagnostic
criteria revision3,4 simpliﬁed the diagnostic process, allowing
a more rapid diagnosis.5,6 However, the increasing focus on an
earlier diagnosis of MS, to allow initiation of disease-
modifying therapies, may increase the risk of misdiagnosis,
which remains an important issue in clinical practice.7,8 In
daily clinical practice, the neurologist must pay extreme at-
tention to clinical presentation, since MS diagnostic criteria
are better applicable in patients with typical presentations
suggestive of MS compared to patients with atypical or
nonspeciﬁc symptoms (e.g., headache, arthralgias)9; more-
over, any diagnostic tests that suggest the possibility of an
alternative diagnosis, so-called red ﬂags,10 should be carefully
evaluated. Interpretation of personal history, physical exami-
nation, and results of imaging and laboratory testing by a cli-
nician with expertise in MS remains fundamental in correctly
diagnosing MS.
Nevertheless, the diﬀerentiation of MS from other MS-
mimicking conditions might be diﬃcult. This is due to the low
amount of data available on the frequency of alternative di-
agnoses in real life. Clinical and paraclinical information about
these diseases is also poor, thusmaking it evenmore complicated
to deﬁne which examinations could be useful in the diagnostic
workup to conﬁrm that “no better explanation” exists.
We therefore designed a real-life study aimed at evaluating (1)
the main diseases that mimic MS at clinical onset and their
frequency, (2) the most relevant clinical and paraclinical
characteristics suggesting a diagnosis diﬀerent from MS, and,
ﬁnally, (3) the best diagnostic workup for the exclusion of
other possible explanations of clinical symptoms suggest-
ing MS.
Methods
Setup of a shared diagnostic workup
A restricted subgroup of participants revised the literature in
order to obtain a list of blood, CSF, and instrumental
examinations needed to identify possible alternative
diagnoses.10–13 Then, a shareable list of examinations to be
included in the diagnostic workup was created and submitted
to each center in order to obtain a consensus statement. We
considered an item accepted if agreed on by at least 70% of
centers. The main reasons to reject an item were (1) not
available in all centers, (2) available but not extensively used in
every day clinical practice, since it requires a motivated request
based on a speciﬁc clinical suspicion (e.g., anti-MOG anti-
bodies), (3) too expensive. The minimum set of examinations
suggested by consensus by the panel is reported in table 1.
However, each center was free to exclude some examinations if
considered of no use in relation to the clinical presentation.
Finally, after a revision of the literature, each alternative di-
agnosis was based on the most recent international guidelines,
where possible (i.e., migraine, neuromyelitis optica spectrum
disorder [NMOSD], Bechet disease, Sjo¨gren syndrome, sys-
temic lupus erythematous, Susac syndrome, ﬁbromyalgia)
14–20 and on common clinical practice where clear guidelines
were not available. The diagnosis of nonspeciﬁc neurologic
symptoms associated with atypical MRI lesions of suspected
ischemic origin was formulated, on the base of the clinical
practice, in those patients presenting with nonspeciﬁc (for
MS) neurologic symptoms (e.g., migraine, arthralgia, and
myalgia), normal neurologic examination, no CSF immuno-
globulin G oligoclonal bands (IgG-OB), normal visual evoked
potentials, MRI lesions atypical for MS, without spinal cord
lesions, and at least one major vascular risk factor
(i.e., hypertension, patent foramen ovale, hypercholesterol-
emia). The diagnosis of nonspeciﬁc neurologic symptoms
associated with atypical MRI lesions was reserved for those
cases where no hypothesis about the origin of the MRI lesions
was possible, the symptoms were not suggestive ofMS, and all
the other examinations were normal. The characteristics of
the typical MRI lesions are reported below.
Study population
We included all patients referred to any of the 22 participating
MS centers between March and September 2014 because MS
was suspected, and who required a diagnostic workup, in-
cluding blood, CSF, and instrumental examinations, in order
to conﬁrm the diagnosis of MS.
Inclusion criteria
The 2 main groups were as follows:
1. Patients presenting with symptoms or signs suggestive of
MS.
Glossary
ANA = antinuclear antibodies; CI = conﬁdence interval; CIS = clinically isolated syndrome; CMV = cytomegalovirus; DIS =
dissemination in space; DIT = dissemination in time; ENA = extractable nuclear antigen; IgG-OB = immunoglobulin G
oligoclonal bands;MS = multiple sclerosis; NMO = neuromyelitis optica; NMOSD = neuromyelitis optica spectrum disorder;
OR = odds ratio; UI = under investigation; VEP = visual evoked potentials.
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2. Patients presenting with atypical symptoms or signs but
referred to one of the centers because MS was
suspected, and who required a specialized diagnostic
assessment. Usually these patients were referred to one
of our MS centers by a general neurologist or by an
emergency department physician (i.e., colleagues with-
out speciﬁc experience in MS) and were included,
following a general neurologic examination, if the
hypothesis of an MS diagnosis was not immediately
rejected.
Exclusion criteria
The only exclusion criterion was an already established di-
agnosis of MS.
Clinical and paraclinical examinations
Information about family history, type of ﬁrst clinical
manifestation (motor, sensory, cortical, visual, spinal cord,
or cerebellar), and the co-occurrence of atypical symptoms
or signs (i.e., arthralgia, myalgia, fever, oral ulceration,
xerophthalmia, xerostomia, rash, migraine, livedo retic-
ularis, epilepsy, gastrointestinal disorders, signs of neu-
ropathy, history of abortion, or thrombosis) were
collected.
During the diagnostic assessment, each patient underwent
a complete neurologic examination, assessed by means of the
Expanded Disability Status Scale21 and a 1.5T brain MRI
according to recent Italian guidelines.22
For each MRI lesion, the size, morphology, and location were
evaluated. Oval, asymmetric white matter lesions perpendic-
ular to the ventricles (Dawson ﬁngers) or in the periven-
tricular, juxtacortical, infratentorial or spinal cord region, and
having a diameter >6 mm, were considered typical of MS.22,23
All other lesions were considered atypical. We also evaluated
the number of contrast-enhancing lesions and the dissemi-
nation in space of the lesions; IgG-OB were investigated
through isoelectric focusing.24 IgG-OB testing in the CSF was
paired with the serum to conﬁrm that IgG-OB were unique
to CSF.
Visual evoked potentials (VEP) were performed, in accor-
dance with International Society for Clinical Electrophysiol-
ogy of Vision international recommendations,25 and latency
and morphology were recorded.
Finally, blood-based examinations were carried out in order to
exclude alternative diagnoses (table 1).
Local ethics committees approved the study. The present
study was conducted in accordance with speciﬁc national laws
and the ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments.
Study design and follow-up
The ﬂowchart of the study is summarized in ﬁgure 1.
At the end of the diagnostic workup, all recruited patients
were classiﬁed into 3 groups according to their diagnosis:
1. MS according to the 2010 revisions of McDonald
diagnostic criteria3
2. Not MS (speciﬁcation of the alternative diagnosis was
required)
3. Under investigation (UI): in case a conclusive diagnosis
could not be formulated, and additional follow-up was
deemed necessary
The latter was further divided into the following:
3a. Clinically isolated syndrome (CIS)/dissemination in
space (DIS)+: patients with a CIS and CIS of the lesions but
lacking dissemination in time (DIT) of lesions and a better
explanation for signs and symptoms
3b. CIS/DIS−/DIT−: patients with CIS but lacking DIS and
DIT; this group included optic neuritis and myelitis (with
negative anti-aquaporin-4 antibodies) with normal brain
MRI scans
3c. CIS/DIS−/DIT+: patients with CIS lacking DIS but with
evidence of DIT (e.g., patients with optic neuritis and 2
periventricular brain lesions, one of which enhanced by
gadolinium)
Each patient without a conclusive diagnosis at the end of the
initial diagnostic workup (3a, 3b, and 3c groups) underwent
a clinical and radiologic 3-year follow-up, in order to assess
Table 1 Minimum set of examinations required to
exclude alternative diagnoses in patients
presenting with clinical symptoms suggestive of
demyelinating diseases of the CNS
Clinical evaluation Laboratory examinations
Neurologic examination with EDSS Complete blood count
CSF examinations AST, ALT, gGT
IgG-OB Kidney profile
IgG index ANA, ENA, and AQP4 aba
Total proteins Homocysteine
Cell count Antithyroid Ab
CSF/serum albumin ratio Vitamin B12 and folate
Instrumental examinations Antiphospholipid Ab
VEP ESR and CRP
MRI Urine examination
Abbreviations: Ab = antibodies; ALT = alanine transaminase; ANA = antinu-
clear antibodies; AQP4 = anti-aquaporin 4; AST = aspartate transaminase;
CRP = C-reactive protein; EDSS = Extended Disability Status Scale; ENA =
extractable nuclear antibodies; ESR = erythrocyte sedimentation rate; gGT =
γ-glutamyltransferase; IgG-OB = immunoglobulin G oligoclonal bands; VEP =
visual evoked potentials.
a Anti-AQP4 antibodies were mandatory in case of symptoms/signs sug-
gestive of optic neuritis or myelitis.
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whether DIS or DIT occurred. During this period, each pa-
tient was evaluated at least every 6 months and underwent
a newMRI at least every year. At the end of the 3 years, based
on the clinical and radiologic follow-up, each patient of the
previous UI group was reclassiﬁed as MS, not MS (with
a deﬁnitive alternative diagnosis), or still as UI. Since the 2017
revised diagnostic criteria for MS were published during the
course of the study,4 each diagnosis was revised, and each
patient reclassiﬁed according to the new criteria.
Recurrent optic neuritides or myelitides that did not show
DIS at the end of the follow-up were included in the not-MS
group.
Statistical analysis
The χ2 test was applied to test the eﬀect of IgG-OB, type,
number, and location of MRI lesions and VEP abnormalities in
identifying MS vs not MS patients both at the end of the initial
diagnostic workup and at the end of the follow-up period.
For each variable, we also calculated sensitivity, speciﬁcity,
and accuracy.
A logistic multivariate analysis was performed, using the oc-
currence of an alternative diagnosis at the end of the study as
dependent variable. As independent variables at baseline, we
included the presence of atypical MRI lesions, the location of
the lesions (periventricular, juxtacortical, infratentorial, spinal
cord), DIS of lesions, the number of contrast-enhancing
lesions, the presence/absence of IgG-OB, the VEP results, the
presence of atypical symptoms, and any signiﬁcantly abnor-
mal blood assay.
Data availability statement
The entire dataset, including all data used in this study, and
completely anonymized, is located in a Dropbox folder and
will be shared following request by qualiﬁed investigators.
Results
Results after the initial diagnostic workup
According to inclusion/exclusion criteria, 695 patients (481
female, mean age 40.6 years) were enrolled in this study.
At the end of the initial diagnostic workup, an alternative di-
agnosis was formulated in 94 patients (13.5%); among these,
nonspeciﬁc neurologic symptoms associated with atypical MRI
lesions of suspected ischemic origin (4.3% of the total di-
agnoses and 31.9% of the alternative diagnoses) was the most
frequent alternative diagnosis. Migraine associated with atypical
MRI lesions (3.2% of the total diagnoses and 23.4% of the
alternative diagnoses) and NMOSDs (1.6% of the total di-
agnoses and 11.7% of the alternative diagnoses) were the other
most frequent diagnoses (table 2 for more details).
According to the 2010 revision of diagnostic criteria, an MS
diagnosis was possible in 286 (41.2%) patients while a con-
clusive diagnosis was not reached in 315 (45.3%) patients,
who remained under investigation. Among these 315 patients
without a deﬁnite diagnosis, 206 showed DIS of MRI lesions
(CIS/DIS+) and 102 showed both DIS and IgG-OB. Fol-
lowing the publication of the 2017 revision of MS diagnostic
criteria, the latter group was reclassiﬁed as MS. Therefore,
among the 695 patients included in the study, the application
of the 2017 revision of diagnostic criteria has allowed the
Figure Study algorithm
*Including patients with symptoms or signs suggestive of
multiple sclerosis (MS) presenting to one of the centers or
patients sent to one of our centers by their physician or by
the local emergency department with suspected MS.
**Within the bracket number according to 2017 diagnostic
criteria. CIS/DIS+ = clinically isolated syndrome with dis-
semination in space of the lesions; CIS/DIS− = clinically iso-
lated syndrome without dissemination in space of the
lesions.
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Table 2 Main diagnoses of the patients included in the
study at the end of the diagnostic workup or at
the end of the 3-year follow-up period
Diagnosis at the end of initial diagnosticworkup
Total
(695) %
Under investigationa 213
(315)
30.6
(45.3)
Multiple sclerosisa 388
(286)
55.8
(41.1)
Nonspecific neurologic symptoms associated
with atypical MRI
lesions of suspected vascular originb
30 4.3
Migraine 22 3.2
NMOSD 11 1.6
Sjo¨gren syndrome 4 0.6
Behçet disease 3 0.4
Antiphospholipid syndrome 2 0.3
Chronic inflammatory demyelinating
polyneuropathy
2 0.3
Systemic lupus erythematosus 2 0.3
Subcombined degeneration spinal cord 2 0.3
Nonspecific neurologic symptoms with
nonspecific MRIc
2 0.3
Arteritic anterior ischemic optic
neuropathy
2 0.3
ADEM 1 0.1
Atypical facial pain 1 0.1
Fibromyalgia 1 0.1
Glaucoma 1 0.1
Hereditary spastic paraplegia 1 0.1
Metabolic leukoencephalopathy 1 0.1
Polyneuritis cranialis 1 0.1
Psychiatric disorder 1 0.1
Spinocerebellar ataxia 1 0.1
Myotonic dystrophy type 1 1 0.1
Susac syndrome 1 0.1
Syringomyelia 1 0.1
Diagnosis at the end of the study Total
(667)
%
Multiple sclerosisa 401
(355)
60.1
(53.2)
CIS/DIS+/DIT2a 28 (78) 4.2
(11.7)
CIS/DIS2/DIT2a 62 (71) 9.3
(10.6)
CIS/DIS2/DIT+a 13 (0) 2.0 (0)
Table 2 Main diagnoses of the patients included in the
study at the end of the diagnostic workup or at the
end of the 3-year follow-up period (continued)
Diagnosis at the end of initial diagnosticworkup
Total
(695) %
Nonspecific neurologic symptoms associated
with atypical MRI
lesions of suspected vascular originb
40 6.0
Migraine with atypical MRI lesions 24 3.6
NMOSD 14 2.1
Nonspecific neurologic symptoms with atypical
MRIc
10 1.5
Recurrent optic neuritis 7 1.0
Behçet disease 7 1.0
Sjo¨gren syndrome 6 0.9
ADEM 6 0.9
Psychiatric disorder 5 0.7
Antiphospholipid syndrome 5 0.7
Fibromyalgia 4 0.6
Systemic lupus erythematosus 4 0.6
Hereditary spastic paraplegia 4 0.6
Susac syndrome 4 0.6
Chronic inflammatory demyelinating
polyneuropathy
3 0.4
Arteritic anterior ischemic optic neuropathy 3 0.4
Subcombined degeneration spinal cord 3 0.4
Glaucoma 2 0.3
Undifferentiated connective tissue disease 2 0.3
Atypical facial pain 2 0.3
Cerebellar hamartoma 1 0.1
Metabolic leukoencephalopathy 1 0.1
Myasthenia gravis 1 0.1
Polyneurits cranialis 1 0.1
Recurrent myelitis 1 0.1
Spinocerebellar ataxia 1 0.1
Myotonic dystrophy type 1 1 0.1
Syringomyelia 1 0.1
Abbreviations: ADEM = acute disseminated encephalomyelitis; CIS/DIS+ = clini-
cally isolated syndrome with dissemination in space of the lesions; CIS/DIS− =
clinically isolated syndrome without dissemination in space of the lesions; DIT =
dissemination in time; NMOSD = neuromyelitis optica spectrum disorder.
a Data are according to 2017 diagnostic criteria (and 2010 diagnostic
criteria).
b This group included patients with atypical MRI lesionswithout IgG-OBs and
spinal cord lesions, with normal VEP and with several vascular risk factors
(i.e., hypertension, patent foramen ovale, hypercholesterolemia).
c This group included patients where no hypothesis about the origin of the
symptom or of the MRI lesions was possible.
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identiﬁcation of 388 (55.8%) patients with MS (instead of
286, according to the 2010 criteria) while a conclusive di-
agnosis was missing in only 213 (30.6%) patients (instead of
315, table 2 for more details).
Results at the end of the study
Among the 315 patients without a deﬁnite diagnosis during
the initial diagnostic workup, 28 were lost to follow-up, while
287 completed a 3-year clinical and radiologic follow-up
(mean 36.6 ± 4.1, range 34–40 months).
At the end of the follow-up, an alternative diagnosis was made
in an additional 69 patients. Among the 667 patients who
completed the study, an alternative diagnosis was formulated
in 163 (24.4%) patients (ﬁgure 1 for more details). Non-
speciﬁc neurologic symptoms associated with atypical MRI
lesions of suspected ischemic origin (24.5% of the alternative
diagnoses) and migraine associated with atypical MRI lesions
(14.7% of the alternative diagnoses) were still the main al-
ternative diagnoses. Table 2 summarizes the total alternative
diagnoses at the end of the study.
Table 3 Role of the main paraclinical tests in the identification of alternative diseases
Not MS (163), n (%) MSa (401), n (%) Under investigation (103), n (%)
Absence of CSF IgG-OB 121 of 135 (89.6) 38 of 344 (11.0) 49 of 103 (47.6)
Atypical MRI lesions 109 of 163 (66.9) 34 of 401 (8.5) 29 of 103 (28.1)
Normal VEP 117 of 151 (77.5) 161 of 351 (45.9) 62 of 98 (63.3)
No DIS 97 of 163 (59.5) 0 of 401 33 of 103 (32.0)
GAD + lesions 13 of 158 (8.2) 155 of 369 (42.0) 9 of 103 (8.7)
Spinal cord lesions 33 of 146 (22.6) 269 of 368 (73.1) 36 of 101 (35.6)
Abbreviations: DIS = dissemination in space of the lesions; GAD = gadolinium; IgG-OB = CSF IgG oligoclonal bands;MS =multiple sclerosis; VEP = visual evoked
potentials.
a The diagnosis of MS was formulated according to the 2017 diagnostic criteria.
Table 4 Sensitivity, specificity, and predictive values of atypicalMRI lesions, lack of dissemination in space (DIS) of lesions,
absence of CSF oligoclonal bands, and normal visual evoked potentials (VEP), for the not multiple sclerosis (MS)
diagnosis
No. of
patients Sensitivity Specificity PPV NPV
Based on the patients who received a not-MS diagnosis at the end of
diagnostic workup
Presence of atypical MRI lesions 77 66.9
(62.7–71.0)
76.3
(72.3–79.9)
40.8
(36.6–45.3)
90.4
(87.5–92.8)
No MRI DIS 91 59.5
(55.2–63.9)
75.4
(71.3–79.0)
35.4
(31.3–39.8)
89.1
(86.0–91.6)
Normal VEP 84 77.5
(76.2-79-0)
45.1
(43.2–48.8)
17.9
(15.1–19.3)
92.5
(90.1–95.2)
Absence of CSF IgG-OB 67 89.6
(86.5–91.7)
69.8
(66.2–73.2)
31.6
(27.0–35.6)
97.7
(96.2–98.6)
Based on thepatientswho received a not-MS diagnosis at the endof 3-
year follow-up
Presence of atypical MRI lesions 46 73.9
(70.1–75.3)
66.7
(63.8–68.9)
69.4
(67.3–71.8)
70.4
(68.4–73.2)
No MRI DIS 63 67.2
(65.2–70.0)
81.5
(79.7–83.6)
100 64.8
(62.3–67.7)
Normal VEP 56 64.3
(62.1–67.6)
38.4
(36.3–40.1)
80.6
(78.6–82.9)
20.2
(18.3–23.1)
Absence of CSF IgG-OB 51 80.4
(78.2–82.1)
62.0
(60.1–64.3)
79.1
(77.3–81.5)
68.8
(66.1–70.9)
Abbreviations: IgG-OB = immunoglobulin G oligoclonal bands; NPV = negative predictive value; PPV = positive predictive value.
Data are reported as % (95% CI).
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The diagnosis of MS was made according to the 2010 di-
agnostic criteria in 355 patients, while in 149 patients it was
not possible to reach a conclusive diagnosis. Among these,
78 patients showed only DIS of MRI lesions (CIS/DIS+/
DIT−) while 71 did not show DIS or DIT (CIS/DIS−/
DIT−). There were no CIS/DIS−/DIT+ patients. How-
ever, following the application of the 2017 revision of di-
agnostic criteria, 401 patients were reclassiﬁed as MS,
whereas only 103 were still under investigation. Among
these 103 patients, 28 patients showed only DIS of MRI
lesions (CIS/DIS+/DIT−), 62 did not show DIS or DIT
(CIS/DIS−/DIT−), and 13 showed only DIT (CIS/DIS−/
DIT+) (table 2).
The role of clinical presentation and
paraclinical tests
Among the 695 patients included in the study, 653 patients
presented with symptoms suggestive of MS (168 sensory,
145 visual, 127 brainstem or cerebellar, 101 motor, 21 cor-
tical, 91 multifocal), 42 patients presented only with atypical
symptoms, and 92 patients showed concomitant typical and
atypical symptoms. The main atypical symptoms were mi-
graine, arthralgia, and myalgia. No signiﬁcant diﬀerence in
the type of the ﬁrst clinical manifestation or in the presence
of atypical symptoms was observed between groups (data
not shown).
The CSF was examined in 593 (85.3%) patients, VEPs were
collected in 610 (87.8%) patients, brain MRI was collected
in all patients, and the complete set of laboratory exami-
nations was carried out in 602 (86.7%) patients. In addi-
tion, gadolinium was administered in 635 (91.3%) patients
and spinal cord MRI was performed in 623 (89.6%)
patients.
The results of the main paraclinical tests in the 3 groups
(MS, not MS, and UI) at the end of the study are reported
in table 3. The sensitivity and speciﬁcity of the main par-
aclinical tests are reported in table 4. The presence of
atypical MRI lesions and the absence of DIS and of CSF
IgG-OB showed the highest accuracy in the identiﬁcation
of not MS patients (table 4 for more details). The re-
lationship between the site of MRI lesions and the ﬁnal
diagnosis is reported in ﬁgure e-1 (doi.org/10.5061/dryad.
33770ms).
The role of hematologic, immunologic, and
rheumatologic screening
Among the blood tests performed in the not MS group of
patients, abnormal results were present in 67 patients: ab-
normal values of antinuclear antibodies/extractable nuclear
antigen (ANA/ENA) antibodies (>1:640 dilutions) were
observed in 13 and anti-aquaporin-4 antibodies in 12 patients,
homocysteine was increased in 10 patients, anti-thyroid
antibodies were observed in 9, and antiphospholipid anti-
bodies in 8 patients; abnormally low levels of B12 and folate
were observed in 8 patients and antineutrophil cytoplasmic
antibodies and immunoglobulin M antibodies against
Epstein-Barr virus, cytomegalovirus (CMV), varicella-zoster
virus, herpes simplex virus 1, measles, and rubella in 1 patient
each.
The abnormal results of blood-based examinations were
crucial for the conclusive diagnosis only in 24 cases: anti-
aquaporin-4 antibodies drove the diagnosis in 12 of the 14
neuromyelitis optica (NMO) cases, increased levels of
homocysteine (6 cases) and the presence of antiphospholipid
antibodies (2 cases) were helpful in the diagnosis of non-
speciﬁc neurologic symptoms associated with atypical MRI
lesions of suspected vascular origin and antiphospholipid
syndrome, respectively; the evidence of low vitamin B12 levels
was helpful in the identiﬁcation of 2 cases of subacute com-
bined degeneration of the spinal cord, while the presence of
ANA/ENA antibodies was helpful in 2 cases of systemic lupus
erythematosus.
Predictors of alternative diagnoses
The multivariate analysis revealed that the absence of IgG-
OBs (p &#60given-names> 0.001, odds ratio [OR] 18.113,
95% conﬁdence interval [CI] 15.123–21.463), the presence of
atypical MRI lesions (p &#60given-names> 0.001, OR
10.977, 95% CI 9.011–13.103), the absence of DIS of the
lesions (p = 0.002, OR 5.164, 95% CI 3.226–7.338), and
normal visual evoked potentials (p = 0.008, OR 3.550, 95%CI
2.011–5.121) were all independent predictors of an alterna-
tive diagnosis and should be considered red ﬂags for the
misdiagnosis of MS. Of note, the presence of abnormal blood
examinations did not reach statistical signiﬁcance.
Discussion
The concept of no better explanation is a key element of all
MS diagnostic criteria revisions1–4,10; however, little has been
done in recent years to gather information on diseases that are
part of the diﬀerential diagnosis of MS in real life. Diagnostic
criteria were created to predict the development of MS in
patients with a CIS suggestive of inﬂammatory demyelination
and, therefore, with a clinical presentation typical for MS.
When used in a diﬀerent context, however, these criteria
might not perform as well in distinguishing MS from other
disorders since they could be fulﬁlled by several other neu-
rologic diseases, leading to possible misdiagnoses and in-
appropriate treatments.
The European Magnetic Resonance Network in MS (MAG-
NIMS) expanded the criterion of the no better explanation
over a decade ago by establishing, mostly on the basis of
literature, some red ﬂags that should help clinicians in the
diﬀerential diagnosis of MS.10 Recently, the same group
suggested a diagnostic algorithm13 that incorporates features
that have been identiﬁed as useful in diﬀerentiating MS from
NMOSD and imaging features that suggest alternative di-
agnoses in the current MS diagnostic criteria. This review
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summarized several new developments in the MS imaging
ﬁeld that have occurred in the last decade; it described the
coexistence of age-related changes and vascular diseases that
have been recognized in patients with MS and pose major
diagnostic challenges; ﬁnally, it highlighted those features that
distinguish MS from the newly recognized antibody-mediated
syndromes of NMOSD and acute demyelinating encephalo-
myelitis. The authors stated that several challenges will be
faced in the near future to diﬀerentiate MS from all those
diseases that can mimic it clinically and radiologically. They
concluded that real-world studies on this topic are necessary
and desirable.
The frequency of MS mimics in real life and, hence, their
relevance and eﬀect on everyday clinical practice has remained
largely unexplored. Consequently, a precise and evidence-
based diagnostic workup aimed at the exclusion of other
diseases mimicking MS has not yet been developed.
To better deﬁne the concept of no better explanation, we
performed a prospective longitudinal observational study
that involved 22 highly specialized MS centers. Since this is
a real-life study we decided to include all consecutive
patients who required a diagnostic assessment to conﬁrm/
exclude the diagnosis of MS: this included patients with
a CIS suggestive of MS but also patients without typical MS
signs or symptoms referred to one of our centers with
a suspicion of MS based on the evaluation of a general
physician or a non-MS neurologist.
We also deﬁned, by consensus, the minimum set of
laboratory/paraclinical examinations that should be per-
formed in patients enrolled in the study, in order to ex-
clude most common better explanations of the clinical
presentation (table 1). Since this is a real-life study, each
clinician was still free to exclude some examinations and to
include additional examinations, according to the clinical
presentation. For example, as reported in table 1, anti-
aquaporin-4 antibodies were searched only in case of optic
neuritis or myelitis. This is why not all the examinations
are available for each patient. Nevertheless, the majority of
the patients underwent a comprehensive battery of blood
tests. Finally, since the current diagnostic criteria at the
time of this study were those described in 2011 by Polman
et al.,3 we decided to describe the classiﬁcation of each
patient on the basis of both the 20103 and the 20174 di-
agnostic criteria.
The ﬁrst result of this study was, therefore, a portrait of the
pathologic conditions that mimic MS in the everyday
clinical practice of highly specialized MS centers: among
these, nonspeciﬁc neurologic symptoms associated with
atypical MRI lesions of suspected ischemic origin, mi-
graine, and NMOSD are by far the most common. Re-
garding these diagnoses, it has to be underlined that,
diﬀerently from NMOSD and migraine, for which speciﬁc
diagnostic guidelines are available, the diagnosis of
nonspeciﬁc neurologic symptoms (i.e., a CIS with symp-
toms not suggestive of MS) associated with atypical MRI
lesions of suspected ischemic origin is mainly based on
common clinical practice. In order to make this diagnosis
more consistent across the centers, we asked each center to
include in this group only patients with at least one major
vascular risk factor and no evidence of MS or other
diseases.
Our results are mostly in line with those of a previous study7
aimed at characterizing patients misdiagnosed with MS: as in
our study, migraine, NMOSD, CIS, and nonspeciﬁc MRI
changes were among the most frequent alternative diagnoses.
The main diﬀerences between the 2 studies refer to the fre-
quency of functional disorders and ﬁbromyalgia, which could
be explained by diﬀerences in the recognition of these dis-
orders as well as patient enrollment procedures. As also
highlighted by Solomon et al.,7,8 ﬁbromyalgia was reported
signiﬁcantly more often by the Mayo Clinic neurologists than
by other centers.
The second interesting result was the observation that in
30% of the cases, a conclusive diagnosis was not reached at
the end of the initial diagnostic workup even after applying
2017 revised MS diagnostic criteria.4 Moreover, after
extending the clinical and radiologic follow-up up to 3 years,
we still had 15% of participants without a deﬁnitive di-
agnosis. As expected, 2010 diagnostic MS criteria performed
signiﬁcantly worse than 2017 criteria, with more than 20%
of patients still without a diagnosis at the end of the fol-
low-up.
From a clinical point of view, and in order to deﬁne the best
diagnostic workup for those patients with a CIS suggestive of
MS, it is of interest to analyze the sensitivity and speciﬁcity of
the radiologic and immunologic examinations currently used
in clinical practice.
The presence of atypical lesions, or lesions located in the
subcortical or in the infratentorial white matter and the
absence of IgG-OB, characterized the 163 patients who
received an alternative diagnosis. A similar ﬁnding was
reported for the CIS/DIS− patients. This result was con-
ﬁrmed by the multivariate analysis run in the followed up
subjects that showed that the absence of CSF IgG-OB, DIS
of the lesions, and the presence of atypical MRI lesions
were the most relevant predictors of an alternative di-
agnosis, and should be considered red ﬂags for the mis-
diagnosis of MS.
As far as the blood tests are concerned, the presence of
abnormal examinations did not reach statistical signiﬁcance
at the multivariate analysis. This is in line with previous
evidence showing the inconsistent signiﬁcance for con-
version to clinically deﬁnite MS of blood tests such as
EBNA1 and CMV IgG dosages.26 We observed very few
cases in which one or more blood tests contributed to the
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ﬁnal diagnosis, with the exception of anti-aquaporin-4
antibodies that allowed the identiﬁcation of several NMO
cases, as already reported.27 We do not suggest, therefore,
a comprehensive battery of blood tests in all patients with
clinical and radiologic ﬁndings suggestive of MS, but only
in those patients showing red ﬂags suggestive of alternative
diagnosis.
This study is not without limitations. The ascertainment bias
could be the ﬁrst limitation of this study. This is why, in order
to limit its eﬀect, we included both patients presenting directly
to one of theMS centers with symptoms or signs suggestive of
MS and patients presenting with atypical symptoms or signs
who were referred to one of our MS centers by the general
physician or by non-MS neurologist. Moreover, the entire
battery of blood-based or paraclinical examinations was not
performed in all patients. Although a minimum set of
laboratory/paraclinical examinations was highly recom-
mended, as all centers had very good expertise on MS, they
were free to exclude or add examinations in relation to
patients’ manifestations. The third possible limitation con-
cerns the MRI protocol, which was not standardized across
the centers. However, it has to be pointed out that all centers
followed recent Italian guidelines15; this guarantees a suﬃ-
cient quality of the images that were also comparable between
centers.
Finally, as already acknowledged, the 3-year clinical and ra-
diologic follow-up was not enough to make a ﬁnal—MS/no
MS—diagnosis in all subjects. We will therefore continue to
follow-up all patients without a conclusive diagnosis.
This observational, unsponsored, real-life study, based on
common clinical practice, showed that, among diseases
mimicking MS, nonspeciﬁc neurologic symptoms associated
with atypical MRI lesions of suspected vascular origin, mi-
graine associated with atypical MRI lesions, and NMOSD
were the main alternative diagnoses.
The absence of IgG-OBs and of DIS, the presence of atypical
MRI lesions, and normal VEP should be considered red ﬂags
for the misdiagnosis of MS. Despite the inclusion of several
blood tests in the study, only a few of these (in particular, anti-
aquaporin-4 antibodies) proved to be relevant in obtaining
a conclusive alternative diagnosis.
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